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SUMMARY
Cellular proliferation depends on refilling the tri-
carboxylic acid (TCA) cycle to support biomass pro-
duction (anaplerosis). The twomajor anaplerotic path-
ways in cells are pyruvate conversion to oxaloacetate
via pyruvate carboxylase (PC) and glutamine con-
version to a-ketoglutarate. Cancers often show an or-
gan-specific reliance on either pathway. However, it
remains unknown whether they adapt their mode of
anaplerosis when metastasizing to a distant organ.
We measured PC-dependent anaplerosis in breast-
cancer-derived lung metastases compared to their
primary cancers using in vivo 13C tracer analysis. We
discovered that lung metastases have higher PC-
dependent anaplerosis compared to primary breast
cancers.Basedon invitroanalysisandamathematical
model for the determination of compartment-specific
metabolite concentrations, we found that mitochon-
drial pyruvateconcentrationscanpromotePC-depen-
dent anaplerosis via enzyme kinetics. In conclusion,
we show that breast cancer cells proliferating as
lung metastases activate PC-dependent anaplerosis
in response to the lung microenvironment.
INTRODUCTION
Most proliferating cells, such as cancer cells, exploit the tricar-
boxylic acid (TCA) cycle for biomass precursor production
(Pavlova and Thompson, 2016), a process that is critically
dependent on sufficient anaplerosis. One important route to refill
the TCA cycle occurs via the enzyme pyruvate carboxylase (PC),
which converts pyruvate to oxaloacetate. Glycolysis-fueling nu-
trients such as glucose and pyruvate are in vitro and in vivo the
major carbon sources providing PC with its substrate pyruvate
(Davidson et al., 2016; Hensley et al., 2016; Sellers et al.,
2015). The alternative route to PC-dependent anaplerosis is
glutamine anaplerosis, and a reciprocal relationship between
both modes of TCA cycle anaplerosis has been established
(Cheng et al., 2011).
PC is transcriptionally and metabolically regulated. Several re-
gulators such as peroxisome proliferator-activated receptor-g,
hepatocytenuclear factor 3b, forkhead/wingedhelix transcription
factorbox2,or upstreamstimulatory factors1/2areknown toalter
PC expression (Boonsaen et al., 2007). Yet, additional mecha-
nisms exist by which PC activity is regulated on ametabolic level.
Thesemechanisms include the inhibitory effects of glutamate and
a-ketoglutarate on PC activity, but also many mechanisms that
are directly or indirectly connected to pyruvate availability (Zec-
zycki et al., 2010). PC is a mitochondrial enzyme, and fueling of
PC with glycolysis-derived pyruvate depends on the activity of
the mitochondrial pyruvate carrier (MPC) (Vanderperre et al.,
2015). Once pyruvate is in themitochondria, it is available as sub-
strate forPCand thuscanpromotePCactivity viaenzymekinetics
(Taylor et al., 1969). Moreover, pyruvate has been shown to
decrease the Km of PC for bicarbonate (McClure et al., 1971).
Yet, pyruvate is not only fuelingPC, but also pyruvate dehydroge-
nase (PDH). This conversion results in acetyl-CoAproduction and
thus increased substrate availability for an oxidative TCA cycle,
which contributes to ATP production. Both a high ATP/ADP ratio
and acetyl-CoA have been shown to promote PC activity (Jitra-
pakdeeet al., 2008;Adina-Zadaet al., 2012; vonGlutz andWalter,
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1976; Walter and Stucki, 1970). Thus, transcriptional and meta-
bolic regulation can impact PC activity and therefore pyruvate-
dependent anaplerosis.
In cancers, differential in vivo preference for PC-dependent
anaplerosis versus glutamine anaplerosis has been observed
and linked to altered PC expression (Davidson et al., 2016;
Sellers et al., 2015). The best-studied examples are breast and
lung cancers. In vivo, many breast cancers show low PC-depen-
dent anaplerosis (Deberardinis et al., 2008; Elia et al., 2016),
while themajority of lung cancers show high PC-dependent ana-
plerosis (Fan et al., 2009; Hensley et al., 2016; Sellers et al.,
2015). In addition, it has been observed that a major change in
the microenvironment, such as in vivo versus in vitro cultivation,
shifts RAS-driven lung cancer cells from PC-dependent
anaplerosis to glutamine anaplerosis (Davidson et al., 2016).
Consequently, only in vitro-cultured RAS-driven lung cancer
cells are sensitive to glutamine anaplerosis inhibitors (Davidson
et al., 2016). These findings highlight the importance of
understanding the interaction between microenvironment
and cancer metabolism to select treatments that are effective
in vivo.
An in vivo process inherently linked to changes in themicroen-
vironment is cancer progression toward metastases formation,
which causes most cancer-related deaths. During metastases
formation, cancer cells originating from one specific tissue and
microenvironment migrate to a distant organ and resume prolif-
eration within this new microenvironment. However, whether a
change between two in vivo microenvironments is sufficient to
alter PC-dependent anaplerosis in cells of the same origin, and
by which mechanism this occurs, remains unexplored.
We addressed these questions by measuring PC-dependent
anaplerosis in primary breast cancers and the resulting lung me-
tastases of an orthotopic breast cancer mouse model. We found
that lung metastases have increased PC-dependent anaplerosis
compared to the corresponding primary breast cancers, which
shows that changes in the in vivo microenvironment can
enforce a change in the anaplerosis mode of cells that
share the same cellular origin. Applying a mathematical
model that resolves compartment-specific pyruvate concentra-
tions, we further provide evidence that increased mitochondrial
pyruvate concentrations can promote PC-dependent anaplero-
sis via enzyme kinetics. In conclusion, we show that breast
cancer cells proliferating as lung metastases increase
PC-dependent anaplerosis as a result of an altered in vivo
microenvironment.
RESULTS
Lung Metastases, but Not the Primary Breast Cancers,
Use PC-Dependent Anaplerosis
It has been recently shown that switching lung cancer cells from
an in vitro to an in vivo microenvironment promotes PC-depen-
dent anaplerosis (Davidson et al., 2016). Based on this observa-
tion, we asked whether cancer cells of the same cellular origin
rewire their anaplerosis mode when proliferating within two
different in vivo microenvironments. Such a situation is highly
relevant during cancer progression when cancer cells infiltrate
distant organs and give rise to metastases.
We decided to test whether breast cancers and their resulting
lung metastases show a different degree of PC-dependent
anaplerosis using in vivo 13C tracer analysis (Davidson et al.,
2016; Quaegebeur et al., 2016). For this purpose, we exploited
the highly metastatic 4T1 breast cancer mouse model, which
has a 100% penetrance for lung metastases within a time frame
of days. Thus, if PC-dependent anaplerosis is a function of
changes in the in vivo microenvironment, we expect that primary
breast cancers and the resulting lung metastases show different
degrees of PC-dependent anaplerosis. We infused mice bearing
primary breast cancers and lung metastases with 13C6-glucose,
and we subsequently measured the 13C-labeling patterns of
pyruvate, succinate, and malate in the primary cancer and me-
tastases tissue (Table S1). To estimate the relative changes in
PC-dependent anaplerosis, we compared the malate M+3 and
succinateM+3 from 13C6-glucose (Buescher et al., 2015). Malate
M+3 from 13C6-glucose is generated by PC flux, but can also
arise from an oxidative TCA cycle flux. Succinate M+3 from
13C6-glucose can arise from an oxidative TCA cycle flux, but
not from PC flux (given that reverse succinate dehydrogenase
flux is marginal or not present). Thus, under the prerequisite
that pyruvate enrichment from 13C6-glucose is similar, com-
paring malate M+3 and succinate M+3 allows to conclude on
relative changes of PC-dependent anaplerosis between
primary breast cancers and lung metastases. We discovered
that lung metastases had significantly higher PC-dependent
anaplerosis compared to primary breast cancers (Figure 1).
This is a striking result, because it has been shown that breast
cancer cells isolated from lung metastases of the 4T1 mouse
model have a similar low PC-dependent anaplerosis as the
parental 4T1 breast cancer cell line when cultured in the same
in vitro microenvironment (Dupuy et al., 2015). Thus, we
concluded that breast cancer cells can alter their magnitude of
PC-dependent anaplerosis based on a change in the in vivo
microenvironment.
Figure 1. Lung Metastases Show Increased PC-Dependent Ana-
plerosis
Relative PC-dependent anaplerosis in primary breast cancers (C) and lung
metastases (M) from 4T1 mice after 6 hr of infusion with 13C6-glucose (n = 4).
Mass distribution vectors are provided in Table S1. Error bars depict SD.
*p% 0.05 based on a two-tailed paired t test.
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Intracellular Pyruvate Levels and PC Expression Are
Increased in Lung Metastases Compared to Primary
Breast Cancers
Next, we sought to determine the mechanism by which the
microenvironment regulates PC-dependent anaplerosis. Specif-
ically, we investigated whether transcriptional and/or metabolic
regulation of PC occurs in lung metastases compared to the
primary breast cancers. Wemeasured PC expression (transcrip-
tional regulation) and pyruvate, glutamate, and a-ketoglutarate
levels (metabolic regulation). We found that PC expression was
increased in lung metastases compared to primary breast
cancers (Figure 2A), which suggests a role for transcriptional
regulation. The levels of glutamate and a-ketoglutarate, both
known inhibitors of PC activity (Zeczycki et al., 2010), were
respectively unaltered or showed an increasing trend in lung
metastases (Figures 2B and 2C) and thus could not explain the
increase in PC-dependent anaplerosis in lung metastases. Yet,
pyruvate levels were increased in the lungmetastases compared
to the primary breast cancers, suggesting that they could
contribute to increased PC activity (Figure 2D).
Next, we asked which alterations in metabolism resulted in
increased pyruvate levels in lung metastases compared to
the primary breast cancers. To answer this question, we
measured gene expression patterns of enzymes and trans-
porters downstream of pyruvate because decreased expres-
sion of any of them can result in increased pyruvate levels
(Compan et al., 2015; Karlsson et al., 1974; Marchiq et al.,
2015). Specifically, we tested whether the pyruvate-lactate-
converting enzymes lactate dehydrogenase (LDH) a/b, the
monocarboxylase transporters (MCT) 1/4 (that can transport
lactate and pyruvate across the plasma membrane), and
MPC1/2 (that transport pyruvate into the mitochondria) were
differently expressed in lung metastases compared to the pri-
mary breast cancers (Figures 2E–2J). Surprisingly, we did not
observe any significant decrease in the gene expression of
these proteins. Yet, this finding was consistent with the fact
that no lactate accumulation occurred in lung metastases
compared to the primary breast cancers (Figure S1A). There-
fore, we concluded that the increase in pyruvate levels within
the lung metastases was not caused by decreased gene
expression of pyruvate-converting or transporting proteins.
Pyruvate Addition to the Nutrient Microenvironment
Increases Intracellular Pyruvate Levels and Modulates
PC-Dependent Anaplerosis
Next, we investigated whether alterations in the nutrient micro-
environment can result in similar metabolic changes to those
we had observed in lung metastases compared to primary
Figure 2. Pyruvate Levels and PC Expression Are Increased in Lung Metastases
(A and E–J) Relative expression of PC, MPC1/2, MCT1/4, and LDHa/b in primary breast cancers (C) and lung metastases (M) from 4T1 mice (n = 7). Error bars
denote SD.
(B–D) Relativemetabolite levels in primary breast cancers (C) and lungmetastases (M) from 4T1mice (n = 4). Error bars denote SD. **p% 0.01, ***p% 0.005 based
on a two-tailed paired t test.
See also Figure S1.
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breast cancers. Interestingly, it has been shown that replacing
glucose with pyruvate leads to increased intracellular pyruvate
levels (Compan et al., 2015), yet this is not a physiological situa-
tion. Thus, we asked whether adding pyruvate in the presence of
glucose to the in vitro nutrient microenvironment results in
increased intracellular pyruvate levels. We found that addition
of pyruvate resulted in increased intracellular pyruvate levels in
three different breast cancer cell lines (MCF7, MDA-MB-231,
and MDA-MB-468) (Figures 3A–3C). Moreover, lactate and
glutamate levels did not increase upon addition of pyruvate to
the nutrient microenvironment (Figures S1B–S1G), while a-keto-
glutarate levels increased (Figures 3D–3F). Thus, pyruvate
addition to the nutrient microenvironment resulted in
similar metabolic changes than we had observed in lung me-
tastases. This finding consequently indicates that lung me-
tastases could exhibit increased intracellular pyruvate levels
because of increased pyruvate availability in the lung
microenvironment.
To test this possibility, we measured the pyruvate and gluta-
mine levels in the lung interstitial fluid and compared them to
those of blood plasma of healthy BALB/c mice. In line with our
hypothesis that the lung in vivo microenvironment favors PC-de-
pendent anaplerosis over glutamine anaplerosis, we found that
the pyruvate/glutamine ratio was !3-fold higher in the interstitial
fluid of the lungs compared to the blood plasma (Figure 3G). This
is in line with the observation that in lung tissue the protein
expression of the pyruvate transporter SLC16A7 is >3-fold lower
than the expression of the glutamine transporters SLC1A5 and
SLC7A5 (Human Protein Atlas). Thus, these data indicate that
the in vivo lung microenvironment favors PC-dependent anaple-
rosis in cancer cells because of pyruvate availability.
Next, we measured PC-dependent anaplerosis upon pyruvate
addition to the nutrient microenvironment in the three breast
cancer cell lines using 13C6-glucose and
13C3-pyruvate to
correct for any label dilution resulting from pyruvate uptake.
PC-dependent anaplerosis increased upon pyruvate addition
to the nutrient microenvironment (Figures 3H–3J; Table S2),
although neither MPC1/2 expression nor PC expression was
significantly increased (Figure S2). Notably, a 2-fold increase in
intracellular pyruvate levels (that matched our measurements
in lungmetastases) resulted in increased PC-dependent anaple-
rosis in all three breast cancer cell lines, independently of their
basal PC expression (that differed by >4.5-fold; data not shown).
This argues that an increase in intracellular pyruvate levels can
contribute to increased PC-dependent anaplerosis in breast
cancer cells proliferating as lung metastases.
Neither the Cellular Acetyl-CoA Levels nor the ATP/ADP
Ratio Are Altered upon Pyruvate Addition to the Nutrient
Microenvironment
Next, we asked how increased pyruvate levels support PC-de-
pendent anaplerosis. Several possible mechanisms have been
described (Adina-Zada et al., 2012; Jitrapakdee et al., 2008;
Taylor et al., 1969; von Glutz and Walter, 1976; Walter and
Stucki, 1970): (1) pyruvate can stimulate an oxidativemetabolism
and increase the ATP/ADP ratio that in turn promotes PC activity;
(2) pyruvate can increase levels of acetyl-CoA, which is a known
allosteric activator of PC activity; and (3) pyruvate can promote
PC activity via increased substrate availability and thus enzyme
kinetics.
We tested whether any of the abovemechanisms was respon-
sible for the increased PC-dependent anaplerosis upon an
Figure 3. Pyruvate Addition to the Nutrient Microenvironment Increases Intracellular Pyruvate Levels and PC-Dependent Anaplerosis
(A–F) Pyruvate and a-ketoglutarate levels in breast cancer cell lines cultured with increasing amounts of pyruvate in the nutrient microenvironment (nR 3).
(G) Pyruvate to glutamine ratio in the interstitial fluid (IF) of the lungs and in blood plasma of healthy BALB/c mice (nR 3).
(H–J) Relative PC-dependent anaplerosis in breast cancer cell lines cultured with increasing amounts of pyruvate in the nutrient microenvironment (n = 3). Mass
distribution vectors are provided in Table S2. Error bars denote SD. *p% 0.05, **p% 0.01, ***p% 0.005 based on a two-tailed paired t test.
See also Figures S1 and S2.
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increase in intracellular pyruvate levels. We measured the AT-
P/ADP ratio as well as the acetyl-CoA levels (using liquid chro-
matography mass spectrometry) and quantified oxidative TCA
cycle metabolism based on ATP-coupled respiration (using a
Clark electrode) as well as PDH flux (based on radioactive
14CO2 capture from 1-
14C-pyruvate) in breast cancer cell lines
upon pyruvate addition to the nutrient microenvironment. All
these measurements were not significantly changed upon pyru-
vate addition to the nutrient microenvironment in the three cell
lines (Figures 4A–4L). The only exception was ATP-coupled
respiration in MDA-MB-468 cells, which increased upon pyru-
vate addition to the nutrient microenvironment and can be ex-
plained by increased NADH production via serine biosynthesis
(Figure S3). Based on these measurements, we concluded that
neither the cell average ATP/ADP ratio nor acetyl-CoA levels
correlated with the relative changes in PC-dependent anaplero-
sis upon pyruvate addition to the nutrient microenvironment.
The Molar Distribution of Pyruvate between the
Mitochondria and the Cytosol Can be Calculated Based
on 13C Labeling Data
Metabolite concentrations can alter metabolite conversion rates
via enzyme kinetics as long as enzyme saturation is not reached
(Fendt et al., 2010;Parket al., 2016). Themetabolite concentration
that leads to 50%enzymesaturation (assuming standardMichae-
lis-Menten kinetics) defines the so-called Km value of an enzyme.
Because PC is a mitochondrial enzyme, pyruvate concentration
alterations within the mitochondria that are below or in the range
of the Km value for PC can promote PC-dependent anaplerosis
via enzyme kinetics. To test for this possibility, we decided to
investigate the compartment-specific distribution of pyruvate.
Standard metabolomics approaches can only report cell-
average metabolite levels, because metabolites are extracted
from the entire cell. Thus, the information on how much of a
metabolite is located within different compartments such as
the cytosol and the mitochondria is lost. Therefore, we decided
to develop a mathematical model that allowed us to determine
the molar amount of mitochondrial and cytosolic pyruvate based
on 13C labeling data.
The basis of this model is that conservation of mass applies
when extracting a metabolite from a cell with different compart-
ments (Figure 5A). The conservation of mass for the compart-
mentalized molar amounts of a metabolite reads:
ntotal =
XN
k = 1
nk (Equation 1)
Here, nk is the molar amount of a metabolite in the compart-
ment k, with k ranging from 1 to N, and ntotal is the molar amount
of that metabolite within the entire cell.
Figure 4. Neither the ATP/ADP Ratio nor Acetyl-CoA Levels Corre-
late with PC-Dependent Anaplerosis
(A–C) Relative PDH flux in breast cancer cell lines cultured with 1 or 5 mM of
pyruvate in the nutrient microenvironment (n = 3). PDH flux was measured
based on the normalized 14CO2 production from 1-
14C-pyruvate.
(D–F) ATP-coupled respiration in breast cancer cell lines cultured with or
without 5 mM of pyruvate in the nutrient microenvironment (n = 6). ATP-
coupled respiration was assessed by the difference between total oxygen
consumption rates and oxygen consumption rates in the presence of the ATP
synthase inhibitor oligomycin A (1 mM).
(G–L) ATP/ADP ratio and acetyl-CoA levels in breast cancer cell lines cultured
with or without 5 mM of pyruvate in the nutrient microenvironment (n = 3). Error
bars denote SD. ***p% 0.005 based on a two-tailed paired t test.
See also Figure S3.
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Moreover, we can further define the molar fraction xk with
which nk (metabolite amount within compartment k) contributes
to ntotal (the amount of the samemetabolite within the entire cell),
xk =
nk
ntotal
(Equation 2)
with
XN
k = 1
xk = 1 (Equation 3)
Consequently, we can compute nk frommeasured xk and ntotal
as nk = xk * ntotal.
With a standard metabolomics approach, we can estimate
ntotal based on the measurement of the amount of the same
metabolite within the entire sample (n) and knowledge of the
number of cells (Z) used to prepare the sample:
ntotal =
n
Z
(Equation 4)
Next, we assumed that eachnk is associatedwith a specific and
known property sk (e.g., a chemical difference such as a stable
isotope enrichment pattern). Consequently, stotal consists of an
average of these compartment-specific properties sk, weighted
by the fractional compartmental contribution xk (Figure 5A),
stotal =
XN
k =1
xk " sk (Equation 5)
Thus, Equation 5 allows estimating xk based on known sk and
measured stotal.
Stable isotope enrichment patterns of a metabolite can be
used as sk and stotal when the biochemical pathways by which
that metabolite is produced differ between compartments:
sk =MDVk (Equation 6)
and
stotal =MDVtotal (Equation 7)
Here, MDV is themass distribution vector, which describes the
fractional abundance of each isotopologue normalized with
the sum of all possible isotopologues, and formally describes
the measured labeling pattern.
Next, we specified our model for pyruvate (because it is our
metabolite of interest) assuming 13C as the stable isotope to
generate compartment-specific stable isotope enrichments in
pyruvate. To do so, we simplified Equations 2, 3, and 5 by
assuming that pyruvate is only present in considerable
amounts within the mitochondria and the cytosol. This
assumption is based on the fact that the major pyruvate
producing and converting enzymes (pyruvate kinase, lactate
dehydrogenase, malic enzyme, pyruvate carboxylase, and
pyruvate dehydrogenase) are located in these two compart-
ments (Genecards database). Although some of these en-
zymes can also be located in the nucleus, small molecules
such as metabolites and proteins below 40 kDa can freely
diffuse through the nuclear pores (Strasser et al., 2012).
Thus, the cytosolic metabolite pool is in complete exchange
with the nuclear metabolite pool. Therefore, applying Equa-
tions 2, 3, 5, 6, and 7 to a two-compartment system (cytosol
(C) and mitochondria (M)) leads to
MDVtotal = xM " MDVM + xC "MDVC (Equation 8)
and
xM + xC = 1 (Equation 9)
Substituting xC = 1 # xM from Equation 9 into Equation 8,
results in
MDVtotal = xM " MDVM + ð1# xMÞ "MDVC (Equation 10)
Here, theMDVtotal is given by the measurement of the
13C label-
ing from pyruvate (MDVP) when metabolites are extracted from
the entire cell:
MDVtotal =MDVP (Equation 11)
Figure 5. Compartment-Specific Molar Fractions of Pyruvate Can Be Determined Based on 13C Labeling Patterns
(A) Conservation of mass applies when extracting a metabolite from a cell with different compartments. The metabolite of interest (in our case pyruvate) has in
compartment 1 (red) the specific and known property s1 (e.g., a stable isotope enrichment) and in compartment 2 (blue) the specific and known property s2
(e.g., another stable isotope enrichment). Consequently, when assuming that only two compartments exist, then the property of the total cell extract stotal (purple)
consists of a mix of the compartment-specific properties s1 and s2, weighted by the molar contributions x1 of the metabolite from compartment 1 and x2 of the
metabolite from compartment 2.
(B) The mathematical model requires that lactate is produced from cytosolic (c) pyruvate and alanine from mitochondrial (m) pyruvate, and thus that the
corresponding enzymatic reactions (red arrows) are compartment-specific. In this case, lactate reflects the 13C labeling enrichment of cytosolic pyruvate and
alanine the 13C labeling enrichment of mitochondrial pyruvate. Moreover, a metabolic flux (e.g., mitochondrial malic enzyme flux) needs to exist that results in a
mitochondrial-specific 13C labeling enrichment of mitochondrial pyruvate (orange arrow). The presence of any flux that leads to exchange between cytosolic and
mitochondrial pyruvate does not invalidate the mathematical model but can result in labeling differences between lactate and alanine that are too small to be
measured reliably.
(C) Simulated M+3 labeling of lactate, pyruvate, and alanine against the theoretical molar fraction of mitochondrial pyruvate. Net flux was assumed to occur in
forward direction (flux from cytosolic to mitochondrial pyruvate).
(D) Simulated M+3 labeling of lactate, pyruvate, and alanine against the theoretical molar fraction of mitochondrial pyruvate.
(E and F) Molar fraction of mitochondrial (m) and cytosolic (c) pyruvate estimated from a published dataset (Vacanti et al., 2014) comprising control cells (WT) and
mitochondrial pyruvate carrier (MPC) knockdown (KD) cells. Lactate, pyruvate, and alanine M+0, M+3, or the total mass distribution vector (MDV) (using a least-
squares fit) was used as input to our mathematical model. Molar amounts of mitochondrial and cytosolic pyruvate were based on the estimated molar fractions
and the published total intracellular pyruvate levels. Error bars denote SE.
See also Figures S4, S5, and S6.
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Similarly,MDVM-P andMDVC-P are the
13C labeling patterns of
mitochondrial and cytosolic pyruvate, respectively. However, we
cannot directly measure MDVM-P and MDVC-P, because we
extract all metabolites of a cell regardless of which compartment
they are located in. Thus, we screened for metabolites whose
13C labeling patterns can be easily measured and that specif-
ically reflect the 13C labeling patterns of mitochondrial and
cytosolic pyruvate. Such metabolites, which we called reporter
metabolites, need to fulfill the following prerequisites: (1) they
are produced from either cytosolic or mitochondrial pyruvate
by compartment-specific enzymes, (2) they may not be pro-
duced from any metabolite other than pyruvate, and they should
not be in the media composition, and (3) their 13C labeling pat-
terns must reflect the respective compartment–specific labeling
patterns of pyruvate. Notably, if (1) and (2) are fulfilled, then (3) is
automatically satisfied as long as stable isotope enrichment
(labeling) steady state has been reached. However, (3) might
not be fulfilled during the dynamic 13C enrichment phase. This
is because 13C enrichment dynamics are a function of time as
well as of the fluxes and metabolite pool sizes present between
the labeled substrate, the metabolite of interest, and the reporter
metabolites (Buescher et al., 2015).
Lactate and alanine have the potential to fulfill both prerequi-
sites in in vitro culture conditions (notably, neither lactate nor
alanine fulfill prerequisite (2) in vivo, because both metabolites
are found within the blood, and thus need to be considered to
be part of the media composition) (Figure 5B). Lactate and
alanine are neither in the DMEM formulation nor in dialyzed
serum. Moreover, lactate is produced from cytosolic pyruvate,
and there is strong evidence that alanine is predominantly pro-
duced from mitochondrial pyruvate (Vacanti et al., 2014; Yang
et al., 2014). We verified the latter assumption for MCF7, MDA-
MB-231, and MDA-MB-468 cell lines (Figure S4). One additional
possibility is that alanine is not synthesized de novo, but derived
from protein breakdown.We experimentally excluded this possi-
bility for MCF7, MDA-MB-231, and MDA-MB-468 cell lines (Fig-
ure S5). Thus, under the prerequisite that cytosolic alanine
aminotransferase flux (compared to mitochondrial alanine
aminotransferase flux) and protein breakdown are marginal or
not present, we can assume in steady state that the labeling
patterns of alanine (MDVA) reflect those of mitochondrial
pyruvate (MDVM-P), while the labeling patterns of lactate
(MDVL) reflect those of cytosolic pyruvate (MDVC-P):
MDVM#P =MDVA (Equation 12)
and
MDVC#P =MDVL (Equation 13)
Combining Equations 10, 11, 12, and 13, we formulate that xM
is a function of the cell average 13C labeling patternsmeasured in
pyruvate, alanine, and lactate:
MDVP = xM " MDVA + ð1# xMÞ "MDVL (Equation 14)
and
xM =
MDVP # MDVL
MDVA #MDVL (Equation 15)
By combining Equations 2, 9, and 15, we can calculate the
molar amount of pyruvate within the cytosol (nC-P) and within
the mitochondria (nM-P), as:
nM#P = xM " nP (Equation 16)
and
nC#P = ð1# xMÞ " nP (Equation 17)
Here, nP denotes the total molar pyruvate amount of the entire
cell.
As indicated earlier (and also evidenced by Equation 15), to
obtain a valid solution fromEquation 15, the 13C labeling patterns
of mitochondrial and cytosolic pyruvate, and thus those of
alanine and lactate, need to differ. Biologically, this means that
mitochondrial pyruvate needs to be produced not only from
cytosolic pyruvate, but in addition by another biochemical
pathway that alters the 13C labeling pattern of mitochondrial
pyruvate and thus alanine (Figure 5B). This requires mitochon-
drial malic enzyme (ME) flux. Notably, mitochondrial phos-
phoenolpyruvate carboxykinase (PCK) activity combined with
mitochondrial pyruvate kinase activity would have a similar effect
as mitochondrial ME flux. Yet, activity of cytosolic ME, cytosolic
PCK, alanine cycling, as well as exchange flux between mito-
chondrial and cytosolic pyruvate, all decrease the difference
between 13C labeling patterns of mitochondrial and cytosolic
pyruvate, and thus those of alanine and lactate. To quantify the
influence of these fluxes on the 13C labeling of pyruvate, alanine,
and lactate, we used a flux model (see the Supplemental Exper-
imental Procedures) and simulated the MDVs of pyruvate,
lactate, and alanine based on theoretical flux solutions using
the MATLAB-based software, Metran (Antoniewicz et al.,
2007). Within the theoretical flux solutions, we tested (1) alter-
ations in exchange flux between mitochondrial and cytosolic
pyruvate, (2) alterations in cytosolic ME flux (that has the same
effect as cytosolic PCK flux), and (2) alterations in alanine cycling
(Table S3). We found that increased exchange flux between
mitochondrial and cytosolic pyruvate (but not cytosolic lactate
dehydrogenase or mitochondrial alanine aminotransferase ex-
change flux) decreased the difference between the 13C labeling
patterns of alanine and lactate (Figure 5C; Table S3). The effect
of cytosolic ME flux and alanine cycling on the difference be-
tween the 13C labeling patterns of alanine and lactate was
much less pronounced than that of pyruvate exchange flux (Fig-
ure 5D; Table S3). This is becauseME and alanine cycling flux are
small compared to the glycolytic flux toward cytosolic pyruvate.
Notably, the validity of Equation 15 did not depend on the
presence or absence of pyruvate exchange, cytosolic ME flux,
alanine cycling, or PC flux (Figures 5B–5D; Table S3). Equation
15 only fails if the 13C labeling patterns of alanine and lactate
are identical. Thus, as long as there is a sufficient mitochondrial
ME flux, the accuracy of the results obtained from Equation 15
only depends on measurement accuracy.
Next, we tested whether measured data would allow solving
Equation 15. Because a standard gas chromatograph-mass
spectrometer has a measurement precision of !±1%, we
argued that we need at least an absolute difference of 2% in
the labeling of lactate and alanine to solve Equation 15 reliably.
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We used a published 13C labeling dataset from mitochondrial
pyruvate carrier (MPC) knockdown and control C2C12 myo-
blasts (Vacanti et al., 2014) (Table S4) as input (M+0, M+3, or
entire MDVs) to our mathematical model. Corroborating our hy-
pothesis that measured data are sufficient in their accuracy to
solve Equation 15, we found that MPC knockdown decreased
the mitochondrial fraction of pyruvate by !8-fold (Figure 5E).
Because the results obtained using different inputs (M+0, M+3,
or entire MDVs) to Equation 15 were all very similar, we decided
to always use the fit of the entire MDVs because this takes all iso-
topologues for each metabolite into account. Thus, we next
calculated the molar mitochondrial and cytosolic amount of py-
ruvate based on Equations 16 and 17, which confirmed that the
total molar pyruvate amount in themitochondria decreased upon
MPC knockdown (Figure 5F). Thus, this test shows that we can
resolve the compartment-specific molar pyruvate amounts in
the mitochondria and the cytosol based on our mathematical
model and measured cell average 13C labeling patterns.
Next, we used the developed model to calculate the molar
amount of mitochondrial pyruvate in MDA-MB-231 cells (that
showed sufficient labeling difference in alanine and lactate) in
the presence and absence of the mitochondrial pyruvate carrier
inhibitor UK-5099. Using this pharmacological inhibitor, we ex-
pected reduced molar amount of pyruvate in the mitochondria
and consequently reduced PC-dependent anaplerosis (Table
S5). Indeed, we found that the mitochondrial pyruvate fraction
and the molar amount of mitochondrial pyruvate decreased
upon treatment with UK-5099 (Figures 6A and 6B). To corrobo-
rate our overall findings, we next measured PC-dependent
anaplerosis in the presence and absence of UK-5099. As
expected from our findings, we found that PC-dependent
anaplerosis decreased upon UK-5099 treatment (Figure 6C).
Thus, we concluded that mitochondrial pyruvate is relevant for
altering PC-dependent anaplerosis and this happens likely via
enzyme kinetics.
Mitochondrial Pyruvate Concentrations Are in the Km
Range for Pyruvate Carboxylase
To finally prove that altered pyruvate levels promote PC-depen-
dent anaplerosis via enzyme kinetics, we estimated the mito-
chondrial pyruvate concentration in MDA-MB-231 cells and
compared it to the Km of PC for pyruvate. Based on the molar
amount of pyruvate within the mitochondria (nM-P), the actual
mitochondrial pyruvate concentration (cM-P) can be determined
by estimating the cytosolic (VC-P) and the mitochondrial (VM-P)
cell volume:
cM#P =
nM#P
VM#P
(Equation 18)
To assess mitochondrial cell volume, we performed an immu-
nofluorescence staining of the plasma membrane and the mito-
chondria. Subsequently, we acquired confocal image scans and
performed a three-dimensional (3D) cell reconstruction, which
allowed us to estimate the mitochondrial volume fraction in
MDA-MB-231 cells (Figure 6D). Next, we measured the total
cell volume using a MOXI Z Mini Automated Cell Counter
(ORFLO). The measured total cell volume was multiplied with
the estimated mitochondrial volume fraction, resulting in an
estimate of the mitochondrial cell volume. Based on these
measurements, we estimated the mitochondrial pyruvate
concentration in MDA-MB-231 cells and compared it to the pub-
lished Km value range of 0.15–0.62 mM (McClure et al., 1971;
Scrutton and White, 1974; Taylor et al., 1969). The estimated
mitochondrial pyruvate concentration was 0.42 mM, which is
within in the range of the Km values from literature (Figure 6E).
Accordingly, upon treatment with UK-5099, the mitochondrial
Figure 6. The Mitochondrial Pyruvate Concentration Correlates with PC-Dependent Anaplerosis and Is in the Km Range for PC
(A and B) Molar fraction and molar amount of cytosolic pyruvate in MDA-MB-231 cells treated with and without the mitochondrial pyruvate carrier (MPC) inhibitor
UK-5099 (10 mM) (nR 3), estimated based on our mathematical model. Mass distribution vectors are provided in Table S5. Error bars depict SE.
(C) PC-dependent anaplerosis in MDA-MB-231 cells treated with and without the mitochondrial pyruvate carrier (MPC) inhibitor UK-5099 (10 mM) (nR 3). Mass
distribution vectors are provided in Table S5. Error bars depict SD.
(D) Representative picture of the 3D cellular reconstruction based on immunofluorescence staining. Plasmamembrane andmitochondria are depicted in red and
green, respectively. Total cell volume was measured with an automated cell counter. Error range represents SD.
(E) Mitochondrial (m) pyruvate concentration in MDA-MB-231 cells estimated based on our mathematical model and the experimental determination of the
mitochondrial cell volume with and without treatment of the mitochondrial pyruvate carrier (MPC) inhibitor UK-5099 (10 mM) (nR 3). Error bars depict SD. Grey
area highlights published Km value range of pyruvate for PC. *p% 0.05, **p% 0.01, ***p% 0.005 based on a two-tailed paired t test.
See also Figure S6.
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pyruvate concentration dropped below the Km value range
(Figure 6E). Thus, we concluded that alterations in mitochondrial
pyruvate concentration can directly translate into increased
PC-dependent anaplerosis via enzyme kinetics and conse-
quently can contribute to increased PC-dependent anaplerosis
in lung metastases.
DISCUSSION
Here, we discovered that breast cancer cells proliferating as lung
metastases increase PC-dependent anaplerosis as a result of a
change in the in vivomicroenvironment. Based on the developed
mathematical model that we used to determine mitochondrial
pyruvate concentrations, we provide evidence for a role of meta-
bolic regulation in this process.
Recently, it has been described that switching cells from an
in vitro to an in vivo microenvironment promotes PC-dependent
anaplerosis via regulation at the expression level (Davidson et al.,
2016). Beyond this finding, we show that changes within the
in vivo microenvironment can result in increased PC-dependent
anaplerosis. Similar to the above-mentioned study, we observed
a role for transcriptional regulation in this process. Yet, we pro-
vide evidence for a combined transcriptional and metabolic
regulation resulting in increased PC-dependent anaplerosis.
This discovery adds to the increasing evidence of metabolic
regulation, via metabolite concentrations or metabolite ratios,
as an important regulatory mechanism within cells (Lorendeau
et al., 2015). Moreover, our data imply that the organ-specific
in vivo availability of nutrients, such as pyruvate, can promote
PC-dependent anaplerosis. Consequently, susceptibility of can-
cers to metabolic drugs such as glutamine anaplerosis inhibitors
(currently in clinical trial) (Elia et al., 2016) might be a function of
the in vivo microenvironment. In support of this hypothesis, we
found that not only increased PC expression is sufficient to
render cells insensitive to glutamine anaplerosis inhibition
(Cheng et al., 2011), but also that simply adding pyruvate to
the nutrient microenvironment rescues the proliferation defect
of glutamine anaplerosis inhibitor treated breast cancer cells
(Figures S6A and S6B). Thus, the link between metabolism and
the nutrient microenvironment needs to be considered to select
effective metabolism-based therapies against cancers.
The genetic landscape and the cell origin are known modula-
tors of cellular metabolism (Davidson et al., 2016; Elia et al.,
2016; Yuneva et al., 2012). Yet, whether the in vivomicroenviron-
ment can modulate the metabolism of metastasizing cancers is
poorly defined (Chen et al., 2015;Maher et al., 2012). By studying
in vivo primary cancers and their corresponding metastases (i.e.,
cancers with the same cell origin proliferating in two different
organs), we show that at least PC-dependent anaplerosis is a
function of the organ-specific microenvironment. Our finding is
thereby supported by the observation that breast cancer cells
isolated from lung metastases of the 4T1 mouse model have a
similar low PC-dependent anaplerosis as the parental 4T1 breast
cancer cell line when cultured in the same in vitro microenviron-
ment (Dupuy et al., 2015).
PC-dependent anaplerosis is mainly fueled by glycolytic car-
bon and therefore depends on MPC activity. However, many
cancers show decreased MPC expression (Schell et al., 2014).
Considering this observation and the data we provide, it can
be speculated that the combination of MPC expression and py-
ruvate concentrations available in the microenvironment define
the in vivo dependency of cancer cells on PC-dependent anaple-
rosis. In contrast with two recent publications (Compan et al.,
2015; Schell et al., 2014), we found that activation of MPC
activity with pyruvate does not necessarily result in increased
ATP-coupled respiration. This difference can be explained by
the fact that in both other studies, pyruvate was the sole glyco-
lytic carbon source provided to the cancer cells, while we
provided pyruvate on top of glucose. Consequently, in our
setting, glycolysis can still be used to provide ATP, while this is
not possible when pyruvate is the sole carbon source entering
glycolysis. Thus, this indicates that pyruvate availability in the
nutrient microenvironment can have a pro-proliferative role by
supporting anaplerosis without increasing oxidative metabolism
in the mitochondria.
Finally, we developed a mathematical model that allows the
determination of the compartment-specific molar amounts of
pyruvate from 13C labeling and metabolomics data. Our method
is complementary to the available fluorescence energy reso-
nance transfer (FRET) sensor for pyruvate (San Martı´n et al.,
2013), because, differently to the FRET sensor, we can simulta-
neously determine the cytosolic and mitochondrial pyruvate
concentration during cellular steady state, while the FRET sensor
is suitable to measure dynamic changes in cytosolic pyruvate
upon short-term stimulation. Notably, our mathematical model
can be used in other in vitro cultured cells as long as valid re-
porter metabolites for pyruvate in the tested cells exist. More-
over, it is possible to translate our mathematical model beyond
pyruvate by combining it with genetic engineering of reporter
metabolites. As a proof of concept, we showed that compart-
ment-specific a-ketoglutarate levels can be determined with
our mathematical model based on engineered reporter me-
tabolites (Figures S6C–S6G; Table S6). This shows that our
model can be combined with metabolic engineering to infer the
compartment-specific distribution of metabolites for which no
natural sensor metabolites exist.
EXPERIMENTAL PROCEDURES
Mathematical Model
The derivation and assumptions of the mathematical model are given in the Re-
sults. Notably, the mathematical model can only be applied in vitro, because
in vivo both alanine and lactate are in the blood, and thus the prerequisite that
both metabolites are only produced de novo from pyruvate fails. For each cell
line, we tested the assumption that cytosolic alanine aminotransferase flux pro-
ducing alanine ismarginal or not present (Figure S4). The overdetermined equa-
tion system resulting from the MDVs was solved using the MATLAB build-in
function lscov, which returns the ordinary least-squares solution and SE to a
linear system of equations. All least-squares solutions are based on the simulta-
neous fit of labeling patterns from at least three biological replicates.
Cell Culture Conditions
All cell lines (MCF7, MDA-MB-231, andMDA-MB-468) were cultured in DMEM
without pyruvate containing 10%dialyzed FBS and 1%penicillin/streptomycin
and tested to be mycoplasma free. The media was replaced every 24 hr. Addi-
tional nutrients (13C-labeled or 13C-unlabeled) or drugs (UK-5099,10 mM;
Sigma-Aldrich) were added 24 hr prior to cell harvest. CB839 (Calithera) was
applied for 72 hr at a concentration of 200 nM.
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13C Tracer Analysis
13C tracer analysis has been performed as described before (Fendt et al.,
2013a, 2013b). See also the Supplemental Experimental Procedures.
PDH Flux
The decarboxylation of pyruvate was assessed using 1-14C-pyruvate. See also
the Supplemental Experimental Procedures.
Mouse Models and In Vivo 13C Tracer Analysis
The 4T1 breast cancer mouse model was used, and in vivo 13C tracer analysis
was performed as described previously (Davidson et al., 2016; Quaegebeur
et al., 2016). All animal experiments were approved by the ethics committee
of KU Leuven.
Statistical Analysis
Statistical analysis was performed for each experiment on n R 3 biological
replicates using a two-tailed paired t test. Either SEs or SDs were calculated
as indicated in each figure legend.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.09.042.
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